Expression of tissue inhibitor of metalloproteinase-1, -2, and -3 during neointima formation in organ cultures of human saphenous vein.
暂无分享,去创建一个
[1] G. Angelini,et al. Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointimal formation in human saphenous vein. , 1998, Human gene therapy.
[2] G. Angelini,et al. Prevention of vein graft failure: potential applications for gene therapy. , 1997, Cardiovascular research.
[3] A. Zalewski,et al. Remodeling of autologous saphenous vein grafts. The role of perivascular myofibroblasts. , 1997, Circulation.
[4] A. Clowes,et al. Plasminogen activator inhibitor type 1 and tissue inhibitor of metalloproteinases-2 increase after arterial injury in rats. , 1997, Circulation research.
[5] A. Newby,et al. Increased secretion of gelatinases A and B from the aortas of cholesterol fed rabbits: relationship to lesion severity. , 1997, Atherosclerosis.
[6] S. George,et al. Surgical preparative injury and neointima formation increase MMP-9 expression and MMP-2 activation in human saphenous vein. , 1997, Cardiovascular research.
[7] G. Wilkinson,et al. Development of recombinant adenoviruses that drive high level expression of the human metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and -2 genes: characterization of their infection into rabbit smooth muscle cells and human MCF-7 adenocarcinoma cells. , 1996, Matrix biology : journal of the International Society for Matrix Biology.
[8] M. Davies,et al. Upregulation of basement membrane-degrading metalloproteinase secretion after balloon injury of pig carotid arteries. , 1996, Circulation research.
[9] M. Reidy,et al. The role of plasminogen, plasminogen activators, and matrix metalloproteinases in primate arterial smooth muscle cell migration. , 1996, Arteriosclerosis, thrombosis, and vascular biology.
[10] A. Bowcock,et al. Structure and Characterization of the Human Tissue Inhibitor of Metalloproteinases-2 Gene* , 1996, The Journal of Biological Chemistry.
[11] A. Clowes,et al. Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo. , 1996, Circulation research.
[12] M. Alavi,et al. Synthesis of tissue inhibitor of metalloproteinase-1 (TIMP-1) in rabbit aortic neointima after selective de-endothelialization. , 1996, Atherosclerosis.
[13] A. Newby,et al. Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors or metalloproteinases-1, -2, and -3 in rabbit aortic smooth muscle cells. , 1996, The Biochemical journal.
[14] M. Ferguson,et al. Expression of collagen, interstitial collagenase, and tissue inhibitor of metalloproteinases-1 in restenosis after carotid endarterectomy. , 1996, The American journal of pathology.
[15] K. Iwata,et al. Immunohistochemical analysis of TIMP-3 expression in degenerative retinal disease , 1996 .
[16] S. George,et al. An essential role for platelet-derived growth factor in neointima formation in human saphenous vein in vitro. , 1996, Atherosclerosis.
[17] S. Apte,et al. The Gene Structure of Tissue Inhibitor of Metalloproteinases (TIMP)-3 and Its Inhibitory Activities Define the Distinct TIMP Gene Family (*) , 1995, The Journal of Biological Chemistry.
[18] A. Strongin,et al. Mechanism Of Cell Surface Activation Of 72-kDa Type IV Collagenase , 1995, The Journal of Biological Chemistry.
[19] P. Libby,et al. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[20] P. Libby,et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. , 1994, The Journal of clinical investigation.
[21] G. Murphy,et al. Structure-function relationships in the tissue inhibitors of metalloproteinases. , 1994, American journal of respiratory and critical care medicine.
[22] M. Reidy,et al. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. , 1994, Circulation research.
[23] M. Reidy,et al. Matrix metalloproteinases of vascular wall cells are increased in balloon-injured rat carotid artery. , 1994, Journal of vascular surgery.
[24] E. Lakatta,et al. Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation. , 1994, Circulation research.
[25] P. Libby,et al. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. , 1994, Circulation research.
[26] A. Ferrando,et al. Structure and expression in breast tumors of human TIMP-3, a new member of the metalloproteinase inhibitor family. , 1994, Cancer research.
[27] R. Khokha,et al. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. , 1994, The Journal of biological chemistry.
[28] V. V. van Hinsbergh,et al. Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. Effects of tumour necrosis factor alpha, interleukin 1 and phorbol ester. , 1993, The Biochemical journal.
[29] G. Angelini,et al. Surgical preparation induces injury and promotes smooth muscle cell proliferation in a culture of human saphenous vein. , 1993, Cardiovascular research.
[30] R. Ross. The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.
[31] A. Newby,et al. Involvement of extracellular-matrix-degrading metalloproteinases in rabbit aortic smooth-muscle cell proliferation. , 1992, The Biochemical journal.
[32] J. Heath,et al. Involvement of AP1 and PEA3 binding sites in the regulation of murine tissue inhibitor of metalloproteinases-1 (TIMP-1) transcription. , 1992, Biochimica et biophysica acta.
[33] M. Cockett,et al. The C-terminal domain of 72 kDa gelatinase A is not required for catalysis, but is essential for membrane activation and modulates interactions with tissue inhibitors of metalloproteinases. , 1992, The Biochemical journal.
[34] R. Hembry,et al. The purification of tissue inhibitor of metalloproteinases-2 from its 72 kDa progelatinase complex. Demonstration of the biochemical similarities of tissue inhibitor of metalloproteinases-2 and tissue inhibitor of metalloproteinases-1. , 1991, The Biochemical journal.
[35] G. Angelini,et al. Intimal proliferation in an organ culture of human saphenous vein. , 1990, The American journal of pathology.
[36] L. Liotta,et al. Tissue inhibitor of metalloproteinases-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues. , 1990, The Journal of biological chemistry.
[37] G. Angelini,et al. The future of saphenous vein as a coronary artery bypass conduit. , 1989, European heart journal.
[38] K. Fujimori,et al. Enhanced expression of a glyceraldehyde-3-phosphate dehydrogenase gene in human lung cancers. , 1987, Cancer research.
[39] P. Stephens,et al. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity , 1985, Nature.
[40] D. Bowyer,et al. Endothelial injury and healing in vitro. Studies using an organ culture system. , 1985, The American journal of pathology.
[41] R. Hembry,et al. Immunolocalization of tissue inhibitor of metalloproteinases (TIMP) in human cells. Characterization and use of a specific antiserum. , 1985, Journal of cell science.
[42] M. Bourassa,et al. Atherosclerosis and late closure of aortocoronary saphenous vein grafts: sequential angiographic studies at 2 weeks, 1 year, 5 to 7 years, and 10 to 12 years after surgery. , 1983, Circulation.
[43] W. Rutter,et al. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. , 1979, Biochemistry.
[44] G. Angelini,et al. Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits SMC migration and neointima formation in human saphenous vein , 1998 .
[45] A. Clowes,et al. Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor. , 1996, Arteriosclerosis, thrombosis, and vascular biology.
[46] J. Thyberg. Differentiated properties and proliferation of arterial smooth muscle cells in culture. , 1996, International review of cytology.
[47] M. Reidy,et al. Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. , 1996, Circulation research.
[48] ScienceDirect. Matrix biology : journal of the International Society for Matrix Biology. , 1994 .
[49] R. RPauly,et al. Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation. , 1994 .
[50] H. Birkedal‐Hansen,et al. Matrix metalloproteinases: a review. , 1993, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.